MARKET EYE-India's Sun Pharma gains on US nod for cancer drug

Tue Feb 5, 2013 12:10pm IST

Related Topics

Stocks

   

* Shares in India's Sun Pharmaceutical Industries Ltd 
rose as much as 4.5 percent after the U.S. Food and Drug
Administration approved its generic version of ovarian cancer
drug Doxil made by Johnson & Johnson in the U.S. market.
 
* "Doxil generic approval came in as a positive surprise. This
would add US$70-$100m in high margin sales for FY14 until
further generic competition comes in," CLSA said in a note on
Tuesday.
* Shares in the drugmaker also gained after subsidiary Taro
Pharmaceutical Industries Ltd posted a 42 percent
growth in October-December net profit. 
* Sun Pharma shares were up 3.7 percent as of 0631 GMT.

 (abhishek.vishnoi@thomsonreuters.com /; kaustubh.
kulkarni@thomsonreuters.com)
FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Pricing Controls

REUTERS SHOWCASE

India-China Relations

India-China Relations

India says to defend China border after standoff ahead of Xi visit.  Full Article 

Importing Iron Ore

Importing Iron Ore

As mining curbs bite, India offers market to glut-hit iron ore.  Full Article 

Drug Approval

Drug Approval

Epirus, Ranbaxy win India approval for arthritis drug copy.  Full Article 

Rajan Speaks

Rajan Speaks

RBI chief Rajan says limiting reliance on foreign debt.  Full Article 

Debt & Equity Deal

Debt & Equity Deal

KKR to lend $175 million to GMR Infrastructure - source.  Full Article 

Preparing for IPO

Preparing for IPO

Alibaba boosts IPO as demand strengthens.  Full Article 

India-Vietnam Ties

India-Vietnam Ties

India tightens Vietnam defence, oil ties ahead of China Xi's visit.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage